If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
70.20    0.00 (0.00%)
Bid:
70.30
Ask:
70.80
Spread: 0.50 (0.711%)
Market Cap: £671.89m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CEO succession

16 Apr 2024 07:00

RNS Number : 7054K
Dr. Martens PLC
16 April 2024
 

This announcement contains inside information.

 

16 April 2024

Dr. Martens plc

CEO succession

 

Dr. Martens plc ('the Company') announces that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board is delighted to announce that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season.

Paul Mason, Chair, said "Kenny's contribution to Dr. Martens has been immense. He has spear-headed a brand-first DTC-driven strategy, achieving significant growth, with pairs more than doubling during his tenure. With his focus on product, brand and custodianship he has instilled a strong culture through the organisation. I am grateful that he will ensure an orderly transition to Ije over the coming year, alongside our incoming CFO Giles Wilson."

Lynne Weedall, Senior Independent Director and Chair of the Nomination Committee, said "Ije is an inspirational leader and his experience in helping drive DTC-led growth at Apple will be highly relevant in the coming years. He knows the Company well, having been a Non-Executive Director for three years and we are already benefiting from his brand expertise since he joined as CBO in February. We are delighted that he will be the next CEO."

Kenny Wilson, CEO, said, "Dr. Martens is an incredible brand powered by our fantastic people. After six years in the role, I feel that the time is right to hand over this year, and I am excited that Ije will be my successor. I have enjoyed working with Ije, both as a Board member and in the executive leadership team in recent months, and I have seen his brand knowledge and passion first-hand. I look forward to working with him closely in the year ahead."

Ije Nwokorie, CBO, said, "I am thrilled that I will be the next CEO of Dr. Martens. We have a phenomenal brand, an excellent product range and a passionate culture. I am looking forward to working with Kenny through this transition year."

 

This announcement has been made in accordance with the requirements of 9.6.11 of the UK Listing Rules. The Company confirms that there is no further information required to be disclosed pursuant to paragraph 9.6.13 of the UK Listing Rules.

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465

Beth Callum, Investor Relations Manager Beth.Callum@drmartens.com +44 203 995 2644

 

Press

H/Advisors Maitland +44 207 379 5151

Katharine Spence +44 7384 535739

Gill Hammond, Director of Communications +44 7384 214248

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Company Secretary.

Notes to editors

Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAPLSFAPLEFA
Date   Source Headline
17th Jul 20238:57 amRNSDirector/PDMR Shareholding
14th Jul 20236:08 pmRNSTransaction in Own Shares
14th Jul 20233:15 pmRNSDirector Declaration
14th Jul 20237:00 amRNSCommencement of Share Buyback Programme
13th Jul 202312:24 pmRNSResult of AGM
13th Jul 20237:00 amRNSTrading Statement
12th Jul 20233:59 pmRNSDirector/PDMR Shareholding
11th Jul 20231:59 pmRNSHolding(s) in Company
4th Jul 20239:12 amRNSTotal Voting Rights
4th Jul 20239:00 amRNSDirector/PDMR Shareholding
13th Jun 20231:09 pmRNSDirector/PDMR Shareholding
13th Jun 20239:00 amRNSAnnual Financial Report
7th Jun 20234:37 pmRNSNotification of transaction of PCA of PDMR
5th Jun 20234:49 pmRNSDirector/PDMR Shareholding
5th Jun 20233:00 pmRNSDirector/PDMR Shareholding
1st Jun 202312:03 pmRNSBlock listing Interim Review
1st Jun 202311:00 amRNSTotal Voting Rights
1st Jun 20237:00 amRNSFinal Results
17th May 202311:30 amRNSDirector/PDMR Shareholding
2nd May 20233:12 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSDirector/PDMR Shareholding
14th Apr 20237:01 amRNSCFO retirement
14th Apr 20237:00 amRNSTrading Statement
3rd Apr 20232:54 pmRNSTotal Voting Rights
24th Mar 20237:00 amRNSDirectorate Change
14th Mar 20235:09 pmRNSReplacement Director/PDMR Shareholding
14th Mar 20233:19 pmRNSDirector/PDMR Shareholding
1st Mar 20234:17 pmRNSTotal Voting Rights
15th Feb 20232:16 pmRNSDirector/PDMR Shareholding
6th Feb 20235:30 pmRNSDirector/PDMR Shareholding
1st Feb 202312:12 pmRNSTotal Voting Rights
19th Jan 20237:00 amRNSTrading Statement
13th Jan 20232:11 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:36 pmRNSTotal Voting Rights
14th Dec 20221:35 pmRNSDirector/PDMR Shareholding
1st Dec 20228:38 amRNSTotal Voting Rights
30th Nov 202210:02 amRNSDirector/PDMR Shareholding
24th Nov 20227:00 amRNSHalf-year Report
15th Nov 20223:54 pmRNSBlock listing Interim Review
15th Nov 20223:44 pmRNSDirector/PDMR Shareholding
1st Nov 20227:00 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSTotal Voting Rights
23rd Aug 20222:38 pmRNSDirector/PDMR Shareholding
1st Aug 202211:51 amRNSTotal Voting Rights
14th Jul 202212:33 pmRNSResult of AGM
14th Jul 20227:00 amRNSTrading Statement
6th Jul 20227:00 amRNSConversion Markets - teach-in event
29th Jun 20228:13 amRNSDirector Declaration
16th Jun 202212:16 pmRNSDirector/PDMR Shareholding
14th Jun 20229:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.